AngioDynamics, Inc. (ANGO) Income Statement
ANGO FY2026 at a glance
Fiscal year ended May 31, 2026 · U.S. dollarsANGO revenue and net income
Where ANGO's revenue goes
FY2026Each bar shows an amount and its share of revenue. ANGO kept −11.5% of revenue as net income.
ANGO profit margins
ANGO growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +9.5% | −1.9% | +1.9% | −1.0% |
| Gross profit | +10.9% | +0.1% | +2.2% | +0.0% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ANGO quarterly EPS vs estimates
AngioDynamics beat the analyst EPS estimate in 7 of the last 8 quarters.
ANGO income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.2M | $292.5M | $303.9M | $338.8M | $316.2M | $291.0M | $264.2M | $359.5M | $344.3M | $349.6M |
| Cost of revenue | $145.3M | $134.8M | $149.2M | $164.5M | $150.5M | $134.2M | $113.9M | $114.6M | $117.8M | $125.8M |
| Gross profit | $174.9M | $157.7M | $154.7M | $174.2M | $165.7M | $156.8M | $150.3M | $156.0M | $143.9M | $143.9M |
| Research & development | $29.4M | $26.2M | $31.5M | $29.9M | $30.7M | $36.4M | $29.7M | $29.4M | $25.5M | $25.3M |
| Sales, general & admin | $157.1M | $145.2M | $144.0M | $144.3M | $133.8M | $117.2M | $116.5M | $116.1M | $108.5M | $110.2M |
| Total operating expenses | $214.8M | $197.7M | $347.1M | $225.4M | $194.2M | $192.1M | $317.4M | $165.4M | $158.0M | $155.1M |
| Operating income | −$39.9M | −$40.0M | −$192.4M | −$51.2M | −$28.5M | −$35.3M | −$167.1M | −$9.4M | −$14.2M | −$11.2M |
| Interest income | — | — | — | — | — | — | $907,000 | $5.1M | $3.1M | $2.8M |
| Interest expense | $299,000 | — | $1.6M | $2.7M | $688,000 | $861,000 | $907,000 | $5.1M | $3.1M | $2.8M |
| Income before taxes | −$36.3M | −$34.0M | −$191.6M | −$54.4M | −$29.9M | −$36.1M | −$168.1M | −$14.7M | −$17.3M | −$14.3M |
| Income taxes | $442,000 | −$39,000 | −$7.3M | −$2.0M | −$3.4M | −$4.5M | −$1.3M | −$3.6M | −$11.0M | −$7.2M |
| Net income | −$36.7M | −$34.0M | −$184.3M | −$52.4M | −$26.5M | −$31.5M | −$166.8M | $61.3M | $16.3M | −$7.1M |
| EBITDA | $488,000 | $1.7M | −$6.1M | $12.2M | $11.1M | −$9.3M | −$143.4M | $16.3M | $9.0M | $13.4M |
| EPS (diluted) | −$0.30 | −$0.15 | −$0.39 | −$0.06 | −$0.67 | −$0.46 | $0.09 | $0.82 | $0.73 | $0.74 |
| Gross margin | 54.6% | 53.9% | 50.9% | 51.4% | 52.4% | 53.9% | 56.9% | 43.4% | 41.8% | 41.2% |
| Operating margin | −12.5% | −13.7% | −63.3% | −15.1% | −9.0% | −12.1% | −63.3% | −2.6% | −4.1% | −3.2% |
| Net margin | −11.5% | −11.6% | −60.7% | −15.5% | −8.4% | −10.8% | −63.1% | 17.1% | 4.7% | −2.0% |
| Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.9M | $86.6M | $78.4M | $79.4M | $75.7M | $80.2M | $72.0M | $72.8M | $67.5M | $71.0M | $75.2M | $79.1M |
| Cost of revenue | $32.9M | $37.2M | $36.9M | $37.3M | $33.9M | $37.9M | $33.1M | $32.9M | $30.8M | $32.5M | $39.3M | $38.8M |
| Gross profit | $48.0M | $49.4M | $41.5M | $42.1M | $41.9M | $42.2M | $38.9M | $39.9M | $36.7M | $38.5M | $35.9M | $40.3M |
| Research & development | $8.0M | $8.2M | $7.1M | $7.8M | $6.4M | $6.6M | $6.9M | $6.4M | $6.3M | $6.7M | $8.2M | $8.7M |
| Sales, general & admin | $42.5M | $41.4M | $38.2M | $36.9M | $40.7M | $36.7M | $36.0M | $36.0M | $36.6M | $35.0M | $36.0M | $34.8M |
| Total operating expenses | $55.3M | $69.8M | $47.9M | $44.6M | $52.5M | $48.0M | $48.8M | $51.0M | $49.8M | $53.0M | $235.8M | $53.4M |
| Operating income | −$7.3M | −$20.4M | −$6.4M | −$2.5M | −$10.7M | −$5.8M | −$10.0M | −$11.1M | −$13.1M | −$14.4M | −$199.9M | −$13.1M |
| Interest income | — | — | — | — | — | — | $135,000 | $234,000 | $606,000 | — | $394,000 | $534,000 |
| Interest expense | $88,000 | $105,000 | $88,000 | $102,000 | $4,000 | — | — | — | — | $567,000 | $394,000 | $534,000 |
| Income before taxes | −$7.3M | −$11.0M | −$8.1M | −$6.4M | −$10.8M | −$6.1M | −$4.4M | −$10.8M | −$12.7M | −$14.1M | −$199.7M | −$12.6M |
| Income taxes | −$199,000 | $370,000 | $12,000 | −$5,000 | $65,000 | −$60,000 | −$2,000 | −$110,000 | $133,000 | −$692,000 | −$12.0M | $16.4M |
| Net income | −$7.1M | −$11.4M | −$8.1M | −$6.3M | −$10.9M | −$6.0M | −$4.4M | −$10.7M | −$12.8M | −$13.4M | −$187.7M | −$29.0M |
| EBITDA | −$1.7M | −$5.3M | −$2.4M | −$436,000 | −$4.8M | $2.2M | −$329,000 | $1.8M | −$1.9M | $1.0M | −$4.1M | −$26,000 |
| EPS (diluted) | −$0.04 | −$0.07 | $0.02 | −$0.15 | −$0.10 | −$0.03 | $0.03 | −$0.04 | −$0.11 | −$0.06 | −$0.16 | −$0.05 |
| Gross margin | 59.4% | 57.1% | 52.9% | 53.1% | 55.3% | 52.7% | 54.0% | 54.8% | 54.4% | 54.3% | 47.7% | 50.9% |
| Operating margin | −9.0% | −23.5% | −8.2% | −3.1% | −14.1% | −7.2% | −13.9% | −15.2% | −19.4% | −20.4% | −265.9% | −16.6% |
| Net margin | −8.8% | −13.2% | −10.3% | −8.0% | −14.4% | −7.5% | −6.1% | −14.7% | −19.0% | −18.9% | −249.7% | −36.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ANGO's financial statements (latest annual report filed July 14, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ANGO financial results
In fiscal year 2026 (ended May 31, 2026), AngioDynamics reported revenue of $320.2 million, up 9.5% from the year before. It had a net loss of $36.7 million, a net profit margin of −11.5%. Diluted earnings per share came to −$0.30. Over five years revenue grew at an average rate of 1.9% a year.
See the ANGO stock overview for the latest quote and news, or the ANGO chart for price history and technical indicators.
ANGO income statement FAQ
What is AngioDynamics's annual revenue?
AngioDynamics reported total revenue of $320.2 million for fiscal year 2026, which ended on May 31, 2026. That was up 9.5% from $292.5 million the previous year.
Is AngioDynamics profitable?
No. AngioDynamics reported a net loss of $36.7 million in fiscal 2026, a net profit margin of −11.5%; its operating margin was −12.5%.
What is AngioDynamics's gross margin?
AngioDynamics's gross margin was 54.6% in fiscal 2026: for every $100 of revenue, AngioDynamics kept $55 after the direct cost of its products and services.
How much does AngioDynamics spend on research and development?
AngioDynamics spent $29.4 million on research and development in fiscal 2026, 9.2% of revenue.
How fast is AngioDynamics growing?
Revenue grew 1.9% a year on average over the last five fiscal years, from $291.0 million to $320.2 million.
What are AngioDynamics's earnings per share?
AngioDynamics earned $-0.30 per diluted share in fiscal 2026, compared with $-0.15 a year earlier.
When does AngioDynamics's fiscal year end?
AngioDynamics's fiscal year ends in May. The latest annual report covers the year ended May 31, 2026 and was filed on July 14, 2026.